Tango Therapeutics raises $225 million in stock offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Tango Therapeutics Announces $225 Million Financing
October 23, 2025 7:20 AM EDTBOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 21,023,337 shares of its common stock and pre-funded warrants to purchase up to 3,226,458 shares of its common stock (the Offering). The offering price of each share of common stock is $8.66. The offering price of each pre-funded warrant is $8.659, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded... More
